Skip to main content
. 2012 Dec;19(6):302–307. doi: 10.3747/co.19.1081

FIGURE 3.

FIGURE 3

Progression-free survival (pfs) among patients receiving chemotherapy. Median pfs in the ecf (epirubicin–cisplatin– 5-fluorouracil) or ecx (epirubicin–cisplatin–capecitabine) group was 8.48 months [95% confidence interval (ci): 6.87 to 9.86 months]; it was 8.87 months (95% ci: 6.67 to 10.32) in the elf (etoposide–leucovorin–5-fluorouracil) group (p = 0.6291).